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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S130with [18F]FHBG, we detected CD34-TK75+ human T cells in
the thymus and lymph nodes only in mice that developed
GvHD.
Summary: This "ﬁrst-in-man" study demonstrated the
safety and feasibility of manufacturing both CD34-TK75+ T
cells and [18F]FHBG onsite for administration to patients. A
future upfront haploidentical transplant study will employ
100-fold more CD34-TK75 modiﬁed T cells.Table I
T-Rapa12 DLI T-Rapa6 DLI
Patient Characteristics
Number of Patients 40 44
Age (median, range) 51 (23-69) 48 (26-70)
# Prior Regimens (median, range) 3 (1-5) 3 (1-8)
Non-Hodgkins 19 (47.5%) 23 (52.3%)
Hodgkins/Gray Zone 6 (15.0%) 11 (25.0%)
Other Heme Malignancy 15 (37.5%) 10 (22.7%)
Diagnostic Risk Group, Kahl I 9 (22.5%) 7 (15.9%)
Kahl II 7 (17.5%) 8 (18.2%)
Kahl III 24 (60.0%) 29 (65.9%)
Chemotherapy Refractory 20 (50%) 21 (47.7%)
Kahl III and/or Refractory 29 (72.5%) 36 (81.8%)
Complete Remission (at HCT) 8 (20%) 12 (27.3%)
Chimerism (% donor; median
values)
Day 14 Post-HCT 60%T 35%
Myeloid
44% T 35%
Myeloid
Day 28 Post-HCT 87% T 79%
Myeloid
78%T 85%
Myeloid
Day 100 Past- HCT 94% T 99%
Myeloid
97% T 100%
Myeloid
GVHD
Classical Acute (through day 100) 4/40 (10%) 17/42 (40.5%)176
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In vitro CD34 enrichment of stem cell grafts is widely used for
depleting T cells from the graft. A high ex vivoT cell depletion
enables effective prevention of Graft-Versus Host Disease
(GVHD) e a major complication after allogeneic stem cell
transplantation. Until now, the clinical scale enrichment of
CD34 positive cells is a complex procedure involving
numerous manual steps.
We have developed a fully automated clinical scale process
within a closed sterile system to purify CD34+cells from
human leukapheresis products. In this context, cell washing,
erythrocyte reduction, cell labeling and the conditions for
immunomagnetic separation were optimized.
To determine the process performance, CD34+cells were
separated fromhuman leukapheresis products with an initial
volume of 120 mL to 211 mL (n¼5). We performed colony-
forming unit (CFU) assays, which allowed us to evaluate the
differentiation potential of the enriched cells.
The total processing time was <4 h. The number of enriched
CD34+ cells was 5.4x106 (range: 2.6x106 to 9.8x106). The
average yield was 73% and the average viability of the sepa-
rated CD34+ cells achieved 76% (range: 65.0% to 85.0%). The
depletion of CD34 negative cells was >99.9%. CFU assays per-
formed after the fully automated enrichment process showed
that the CD34+cell fraction contained primitive and multi-
potent progenitor cells, such as CFU-GEMM and CFU-GM.
The cell separation system described provides a safe and easy
way to purify CD34+ cells from leukapheresis within <4 h
without any intermediatemanual steps. The cell preparation in
a closed sterile system facilitates a fast and robust enrichment
ofCD34+cells.Thecells areeluted inavolumeofapproximately
80 mL and can be used directly for further applications.Acute GVHD Grade II (n¼3); III (n¼1) II (n¼14); III
(n¼3)
Acute GVHD Through Day 180,
Total
15/39 (38.5%) 28/42 (66.7%)
Gut involvement 7/39 (17.9%) 30/42 (47.6%)
Median Day of Onset Day 92 Day 70
Classical Chronic 17/37 (45.9%) 17/36 (47.2%)
(60 month
median F/U)
(38 month
median F/U)
Overall Outcome
K-M Survival Probability, Day 100
Post-HCT
95% 93.2%
One-year Post-HCT 75% 79.6%
Two-year Post-HCT 67.5% 63.6%
Current Survival, Overall 21/40 (52.5%) 28/44 (63.6%)
In Sustained CR 18/40 (45%) 21/44 (47.7%)
Death Due to PD (% of all patients) 17/40 (42.5%) 11/44 (25%)
In PR/CR (TRM) 2/40 (5.0%) 3/44 (6.8%)177
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In a phase II clinical trial, pre-emptive DLI using rapamycin-
resistant donor CD4+ T cells manufactured in 12-days
(T-Rapa12 cells) was associated with conversion of mixed
chimerism, GVL effects in patients with refractory hemato-
logic malignancy, and a moderate rate and severity of GVHD
(Blood, 2013). We recently found that culture interval trun-
cation to 6-days yielded T-Rapa6 cells with a unique gene
expression proﬁle (w6% of genes differentially expressed
relative to T-Rapa12 cells; Cytotherapy, 2013). To assess
whether T-Rapa6 cells mediate distinct clinical effects rela-
tive to T-Rapa12 cells, we conducted a sequential phase II
clinical trial (NCT0074490) at the NIH and Hackensack Uni-
versity Medical Center using the exact same low-intensity
transplant platform. T-Rapa6 cells were manufactured by ex
